Higher-Risk Myelodysplastic Syndromes | David Sallman, MD
Overview
David Sallman describes how high-risk MDS treatment may improve by treating TP53-mutated disease as a distinct biological group, regardless of whether blasts fall on the MDS or AML side of an arbitrary cutoff. He reviews magrolimab plus azacitidine data, including responses, anemia precautions, transplant outcomes, and MRD findings, then discusses pivotal trials, sabatolimab, IDH inhibitors after HMA failure, and remaining treatment gaps.
Key takeaways
- TP53-mutated myeloid disease with complex karyotype should be evaluated as a distinct high-risk entity across MDS and AML blast thresholds, because outcomes appear similarly poor across the diagnostic boundary.
- Magrolimab plus azacitidine produced responses in roughly three-quarters of 95 higher-risk MDS patients in a phase 1 cohort, but its early CD47-related anemia requires hemoglobin monitoring and post-infusion blood counts.
- Response depth matters in MDS: blast clearance accompanied by hematologic improvement is more meaningful than blast clearance alone, and MRD negativity was associated with longer survival in non-transplanted patients.
- In the reported TP53-mutated AML cohort, magrolimab-based treatment yielded 11-month median survival versus an approximately six-month benchmark for azacitidine plus venetoclax, but randomized trials are needed to establish comparative benefit.
- For MDS that progresses after hypomethylating-agent therapy, repeat sequencing can uncover targetable mutations; reported IDH inhibitor results include durable responses and a 46% complete remission rate with ivosidenib in IDH1-mutated disease.
- Sabatolimab targets TIM-3 on leukemic stem cells and immune cells, but the phase 2 STIMULUS-MDS2 trial missed its primary endpoints, leaving overall survival results from phase 3 testing important to its clinical role.
Chapters
- A fit 67-year-old man had severe pancytopenia, 12% marrow blasts, a TP53 mutation with 55% variant allele frequency, and a complex karyotype.
- After azacitidine plus magrolimab, he achieved blast clearance, hematologic improvement, and complete remission before allogeneic transplant.
- Sallman argues that TP53-mutated disease should be considered a coherent group across MDS and AML, rather than divided by blast percentage.
- He cites poor existing outcomes in TP53-mutated AML, with median survival around six months on current standard options, as rationale for the ENHANCE-2 phase 3 trial.
- The 2023 International Working Group criteria recognize complete remission equivalents and hematologic improvement with blast clearance as meaningful responses.
- Sallman notes that blast clearance without hematologic improvement generally does not provide the same clinical benefit.
- The International Consensus Classification defines an MDS/AML category for 10% to 90% blasts, while Sallman emphasizes that TP53-mutated cases may behave similarly across these categories.
- Before next-generation sequencing results return, chromosome 5 or 7 abnormalities on MDS FISH, TP53 immunohistochemistry, and ring sideroblast findings can help flag likely TP53-mutated disease.
- Magrolimab blocks CD47, a macrophage “don’t eat me” signal; phagocytosis also depends on pro-phagocytic signals such as calreticulin.
- Azacitidine may increase pro-phagocytic signaling, providing a rationale for combining it with the anti-CD47 antibody.
- The regimen uses a 1 mg/kg priming dose followed by dose escalation, then weekly dosing and every-other-week dosing from cycle 3; continued CD47 receptor saturation is a treatment consideration.
- Red-cell clearance can cause an early hemoglobin drop, so Sallman describes maintaining hemoglobin above 9 g/dL around initial infusions and checking blood counts 3 to 6 hours afterward.
- In a 95-patient higher-risk MDS phase 1 cohort, roughly three-quarters responded, most commonly with complete remission or marrow response plus hematologic improvement.
- Responses could deepen over several cycles: some patients reached complete remission only by cycle 4 or later, supporting time for response assessment when clinically appropriate.
- Median overall survival was not reached at a median follow-up of 17 months; about 40% proceeded to transplant, with reported two-year post-transplant survival approaching 80%.
- Flow-cytometry MRD negativity at a 0.2% cutoff was associated with longer survival, particularly among patients who did not undergo transplant.
- In 72 TP53-mutated AML patients treated with magrolimab-based therapy, the overall response rate was about 50%, complete remission was about 33%, and median survival was 11 months.
- Sallman compares these results with a median survival of about six months for azacitidine plus venetoclax in this population, while noting that the data come from nonrandomized studies.
- ENHANCE-MDS and ENHANCE-2 were described as pivotal randomized trials testing magrolimab-based combinations, including comparisons with azacitidine plus venetoclax or intensive induction in AML.
- TP53 mutations can produce misfolded, dysfunctional protein; Sallman discusses the investigational reactivation strategy eprenetapopt (APR-246) and the challenge of restoring function across different variants.
- TIM-3 is expressed on leukemic stem cells and can support their survival through a galectin-9 signaling loop; it also acts as an immune checkpoint.
- The phase 2 STIMULUS-MDS2 trial compared an HMA with or without sabatolimab and did not meet its primary endpoints for complete remission or progression-free survival.
- Sabatolimab added little cytopenia toxicity in the reported data, while immune-related adverse events were generally manageable.
- The phase 3 STIMULUS-MDS1 trial was described as testing monthly sabatolimab plus azacitidine versus azacitidine alone, with overall survival as its primary endpoint.
- At progression after 12 azacitidine cycles, repeat sequencing identified an IDH2 mutation, prompting consideration of the IDH2 inhibitor enasidenib despite the lack of an MDS-specific label at the time discussed.
- A small retrospective IDH-mutated MDS series reported median survival of about 20 months with IDH inhibitor treatment after HMA failure, compared with roughly six months as a historical benchmark.
- Ivosidenib studies in IDH1-mutated MDS reported a 46% complete remission rate by IWG criteria and durable responses; Sallman says differentiation syndrome appeared less frequent or severe than in AML cohorts.
- Future priorities include TP53-specific approaches, targeted treatments for splicing mutations, MRD-guided therapy, transplant optimization, and understanding relapse mechanisms.
- Sallman reports patients remaining on IDH inhibitors for years, including one patient with normalized blood counts five years after starting treatment.
- In his IDH1-mutated MDS cohort, no grade 3 or higher differentiation syndrome events were reported, with only two grade 2 events.
- FLT3 mutations are rare in MDS, estimated at 1% or less; Sallman says he would treat a patient with FLT3 mutation and 12% blasts as AML.
Transcript excerpt
0:00 hello my name is David Salman from mfet cancer center in Tampa Florida I'm an associate member in the myoid section head in the malignant hematology Department it's really a honor and pleasure to be here and look forward to all of our discussions you know my focus topic will be on future directions in the management of higher risk MDS and we'll really highlight uh several novel therapies as well as think about options that we may have after you know standard of care Frontline therapy and again look forward to these uh discussions so starting out with a case uh we have a 67-year-old male who presents with severe pancitopenia 12% myoblast um trilineage dysplasia and really part of the standard of care workup would be nection sequencing profile and notably it only showed one mutation but showed a p-53 mutation with a very high variant
0:48 alal frequency of 55% as well as Associated complex kype by cytogenetics this patient um is really otherwise fit minimal comorbidity still actually walking a mile per day at the time of presentation and really based on the store poor standard of care in this patient population we discussed clinical trial options and the patient was ultimately enrolled uh on a trial of as aedine with mamab the patient did have a two gram uh drop in the hemoglobin actually about four or five hours after the first infusion and had some notable increased you know symptomatic anemia this was transfused and actually subsequently really had no issues and no infusion related reactions this patient achieved uh marrow response or blast clearance with hologic Improvement and actually subsequently achieved a true complete
1:35 remission by iwg criteria and ultimately brid allergen a cell transplant and again I think this case both highlights an exciting new therapy as well as a
This is the start of the transcript. Save this video free for the whole transcript, searchable and time-coded.
Related notes
Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Research To Practice.